Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peripheral Arterial Disease | 85 | 2024 | 1306 | 21.830 |
Why?
|
Platelet Aggregation Inhibitors | 74 | 2024 | 3201 | 7.910 |
Why?
|
Myocardial Infarction | 88 | 2024 | 11891 | 6.340 |
Why?
|
Lactones | 24 | 2022 | 319 | 5.690 |
Why?
|
Purinergic P2Y Receptor Antagonists | 26 | 2024 | 379 | 5.030 |
Why?
|
Adenosine | 20 | 2023 | 834 | 4.610 |
Why?
|
Lower Extremity | 25 | 2024 | 1194 | 4.500 |
Why?
|
Aspirin | 32 | 2024 | 3364 | 4.280 |
Why?
|
Secondary Prevention | 42 | 2024 | 1548 | 4.060 |
Why?
|
Vascular Surgical Procedures | 14 | 2024 | 1475 | 3.560 |
Why?
|
Acute Coronary Syndrome | 34 | 2024 | 2365 | 3.390 |
Why?
|
Ischemia | 26 | 2024 | 1893 | 3.390 |
Why?
|
Fibrinolytic Agents | 16 | 2024 | 2167 | 3.310 |
Why?
|
Pyridines | 27 | 2022 | 2879 | 3.270 |
Why?
|
Thrombosis | 21 | 2024 | 3052 | 2.900 |
Why?
|
Stroke | 41 | 2024 | 9962 | 2.770 |
Why?
|
Hemorrhage | 42 | 2024 | 3600 | 2.560 |
Why?
|
Troponin I | 10 | 2022 | 638 | 2.380 |
Why?
|
Endovascular Procedures | 12 | 2024 | 2165 | 2.380 |
Why?
|
Atherosclerosis | 21 | 2024 | 3517 | 2.210 |
Why?
|
Drug Therapy, Combination | 27 | 2024 | 6498 | 2.110 |
Why?
|
Aortic Diseases | 5 | 2022 | 736 | 1.990 |
Why?
|
Anticholesteremic Agents | 7 | 2024 | 987 | 1.950 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2024 | 3334 | 1.780 |
Why?
|
Receptor, PAR-1 | 10 | 2019 | 114 | 1.730 |
Why?
|
Treatment Outcome | 91 | 2024 | 65017 | 1.520 |
Why?
|
Venous Thromboembolism | 11 | 2023 | 1864 | 1.470 |
Why?
|
Diabetes Mellitus, Type 2 | 23 | 2024 | 12293 | 1.460 |
Why?
|
Drug-Eluting Stents | 4 | 2023 | 757 | 1.400 |
Why?
|
Thrombolytic Therapy | 8 | 2021 | 2108 | 1.380 |
Why?
|
Dyslipidemias | 4 | 2021 | 895 | 1.320 |
Why?
|
Coronary Artery Disease | 15 | 2024 | 6659 | 1.320 |
Why?
|
Brain Ischemia | 8 | 2022 | 3127 | 1.310 |
Why?
|
Blood Coagulation Disorders | 2 | 2023 | 349 | 1.300 |
Why?
|
Humans | 255 | 2024 | 760621 | 1.230 |
Why?
|
Glucosides | 8 | 2020 | 533 | 1.230 |
Why?
|
Cardiovascular Diseases | 29 | 2024 | 15757 | 1.230 |
Why?
|
Cholesterol, LDL | 7 | 2024 | 2420 | 1.160 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2022 | 2290 | 1.120 |
Why?
|
Double-Blind Method | 43 | 2024 | 12427 | 1.110 |
Why?
|
Embolism | 2 | 2022 | 408 | 1.080 |
Why?
|
Receptors, Thrombin | 5 | 2015 | 132 | 1.060 |
Why?
|
Benzhydryl Compounds | 8 | 2020 | 941 | 1.060 |
Why?
|
Aged | 120 | 2024 | 169152 | 1.040 |
Why?
|
Risk Factors | 71 | 2024 | 74359 | 1.040 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 33 | 1.030 |
Why?
|
Sterol O-Acyltransferase | 2 | 2022 | 28 | 1.020 |
Why?
|
Diabetes Mellitus | 11 | 2023 | 5889 | 1.010 |
Why?
|
Hypolipidemic Agents | 2 | 2021 | 626 | 0.980 |
Why?
|
Coronary Thrombosis | 4 | 2018 | 486 | 0.980 |
Why?
|
Anticoagulants | 15 | 2024 | 4897 | 0.950 |
Why?
|
Troponin T | 6 | 2022 | 774 | 0.930 |
Why?
|
Extremities | 6 | 2021 | 867 | 0.900 |
Why?
|
Randomized Controlled Trials as Topic | 21 | 2024 | 10344 | 0.880 |
Why?
|
Risk Assessment | 31 | 2024 | 24123 | 0.870 |
Why?
|
Middle Aged | 107 | 2024 | 220352 | 0.860 |
Why?
|
Male | 132 | 2024 | 359744 | 0.830 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2022 | 43 | 0.800 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2023 | 418 | 0.790 |
Why?
|
Female | 130 | 2024 | 391270 | 0.780 |
Why?
|
Walking | 5 | 2022 | 1189 | 0.780 |
Why?
|
Limb Salvage | 6 | 2024 | 465 | 0.770 |
Why?
|
Acetanilides | 6 | 2014 | 169 | 0.770 |
Why?
|
Heart Failure | 15 | 2023 | 11847 | 0.730 |
Why?
|
Beneficence | 1 | 2021 | 54 | 0.730 |
Why?
|
Cardiovascular Agents | 4 | 2022 | 867 | 0.720 |
Why?
|
Vascular Diseases | 4 | 2023 | 1182 | 0.700 |
Why?
|
Serine Proteinase Inhibitors | 2 | 2020 | 179 | 0.690 |
Why?
|
Antifibrinolytic Agents | 1 | 2023 | 292 | 0.690 |
Why?
|
Hypercholesterolemia | 2 | 2024 | 1155 | 0.640 |
Why?
|
Research Subjects | 1 | 2021 | 249 | 0.630 |
Why?
|
Atrial Fibrillation | 5 | 2024 | 5209 | 0.630 |
Why?
|
Piperazines | 8 | 2014 | 2525 | 0.630 |
Why?
|
Personal Autonomy | 1 | 2021 | 302 | 0.620 |
Why?
|
Platelet Aggregation | 5 | 2023 | 805 | 0.590 |
Why?
|
Kaplan-Meier Estimate | 16 | 2024 | 6544 | 0.580 |
Why?
|
Outpatients | 3 | 2024 | 1607 | 0.580 |
Why?
|
Kidney Diseases | 5 | 2020 | 2093 | 0.580 |
Why?
|
Chest Pain | 4 | 2017 | 1106 | 0.560 |
Why?
|
Time Factors | 32 | 2024 | 40165 | 0.540 |
Why?
|
Renal Insufficiency | 2 | 2021 | 820 | 0.530 |
Why?
|
Leg | 1 | 2021 | 1090 | 0.530 |
Why?
|
Myocardial Ischemia | 6 | 2021 | 2164 | 0.520 |
Why?
|
Growth Differentiation Factor 15 | 3 | 2023 | 196 | 0.520 |
Why?
|
Follow-Up Studies | 27 | 2022 | 39261 | 0.520 |
Why?
|
Electrocardiography | 8 | 2018 | 6414 | 0.510 |
Why?
|
Acute Disease | 8 | 2021 | 7269 | 0.510 |
Why?
|
Caffeine | 1 | 2020 | 702 | 0.510 |
Why?
|
Lipoproteins, HDL | 4 | 2024 | 667 | 0.500 |
Why?
|
Intermittent Claudication | 4 | 2022 | 306 | 0.500 |
Why?
|
Diabetes Complications | 2 | 2021 | 1341 | 0.490 |
Why?
|
Paclitaxel | 2 | 2021 | 1736 | 0.480 |
Why?
|
Cardiology | 3 | 2022 | 1723 | 0.480 |
Why?
|
Cerebrovascular Disorders | 2 | 2018 | 1501 | 0.480 |
Why?
|
Beverages | 1 | 2020 | 820 | 0.480 |
Why?
|
Sex Characteristics | 2 | 2023 | 2629 | 0.480 |
Why?
|
Dyspnea | 2 | 2020 | 1352 | 0.480 |
Why?
|
Myocarditis | 2 | 2019 | 766 | 0.470 |
Why?
|
Patient Selection | 3 | 2022 | 4283 | 0.470 |
Why?
|
Informed Consent | 1 | 2021 | 1005 | 0.460 |
Why?
|
Ulcer | 2 | 2021 | 204 | 0.450 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2020 | 698 | 0.450 |
Why?
|
Hypoglycemic Agents | 10 | 2024 | 3150 | 0.450 |
Why?
|
Ventricular Function, Left | 3 | 2023 | 3880 | 0.450 |
Why?
|
Syndrome | 5 | 2023 | 3280 | 0.430 |
Why?
|
Hospitalization | 9 | 2023 | 10790 | 0.430 |
Why?
|
Recurrence | 20 | 2024 | 8482 | 0.420 |
Why?
|
Patient Care Team | 1 | 2024 | 2511 | 0.420 |
Why?
|
Lecithins | 2 | 2022 | 17 | 0.420 |
Why?
|
Cholesterol | 4 | 2022 | 2924 | 0.420 |
Why?
|
Apolipoprotein A-I | 2 | 2024 | 297 | 0.420 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2019 | 96 | 0.410 |
Why?
|
Benzazepines | 3 | 2019 | 311 | 0.410 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 60 | 0.400 |
Why?
|
Incidence | 15 | 2024 | 21392 | 0.400 |
Why?
|
Consensus | 2 | 2022 | 3113 | 0.390 |
Why?
|
Heparin | 3 | 2023 | 1652 | 0.360 |
Why?
|
Stents | 4 | 2021 | 3314 | 0.360 |
Why?
|
Drug Administration Schedule | 9 | 2024 | 4899 | 0.360 |
Why?
|
Disease Management | 1 | 2021 | 2514 | 0.360 |
Why?
|
Hematoma | 2 | 2021 | 769 | 0.350 |
Why?
|
Blood Platelets | 5 | 2023 | 2520 | 0.350 |
Why?
|
Databases, Factual | 4 | 2024 | 8035 | 0.350 |
Why?
|
Thiophenes | 2 | 2011 | 587 | 0.350 |
Why?
|
Natriuretic Peptide, Brain | 5 | 2023 | 1717 | 0.340 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2021 | 10827 | 0.340 |
Why?
|
Postoperative Complications | 2 | 2021 | 15697 | 0.320 |
Why?
|
Enoxaparin | 2 | 2021 | 397 | 0.320 |
Why?
|
Thrombin | 3 | 2021 | 593 | 0.320 |
Why?
|
Death, Sudden, Cardiac | 3 | 2018 | 1572 | 0.320 |
Why?
|
Smoking Cessation | 2 | 2024 | 2064 | 0.320 |
Why?
|
Enzyme Inhibitors | 5 | 2014 | 3726 | 0.310 |
Why?
|
Appetite Depressants | 2 | 2019 | 108 | 0.310 |
Why?
|
Prognosis | 15 | 2024 | 29658 | 0.300 |
Why?
|
Prospective Studies | 20 | 2022 | 54303 | 0.290 |
Why?
|
Multicenter Studies as Topic | 5 | 2021 | 1722 | 0.290 |
Why?
|
Medical Oncology | 1 | 2019 | 2313 | 0.290 |
Why?
|
Intracranial Hemorrhages | 5 | 2018 | 844 | 0.280 |
Why?
|
Survival Rate | 6 | 2021 | 12808 | 0.280 |
Why?
|
Factor XI | 2 | 2024 | 34 | 0.280 |
Why?
|
Cause of Death | 7 | 2021 | 3725 | 0.280 |
Why?
|
Patient Readmission | 1 | 2021 | 3323 | 0.280 |
Why?
|
Diabetes Mellitus, Experimental | 2 | 2023 | 1112 | 0.280 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4878 | 0.270 |
Why?
|
Angina Pectoris | 2 | 2009 | 969 | 0.270 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3527 | 0.270 |
Why?
|
Proportional Hazards Models | 11 | 2021 | 12531 | 0.260 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2021 | 861 | 0.250 |
Why?
|
Medicare | 8 | 2024 | 6786 | 0.250 |
Why?
|
United States | 19 | 2024 | 72461 | 0.250 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2012 | 1489 | 0.240 |
Why?
|
Ventricular Function | 1 | 2006 | 408 | 0.240 |
Why?
|
Popliteal Artery | 2 | 2023 | 312 | 0.230 |
Why?
|
Troponin | 3 | 2020 | 516 | 0.230 |
Why?
|
Ankle Brachial Index | 4 | 2022 | 163 | 0.230 |
Why?
|
American Heart Association | 3 | 2022 | 1081 | 0.230 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9185 | 0.230 |
Why?
|
Life Style | 1 | 2015 | 3896 | 0.220 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 2 | 2018 | 334 | 0.220 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2023 | 345 | 0.220 |
Why?
|
Exercise | 2 | 2021 | 5787 | 0.210 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2009 | 1880 | 0.210 |
Why?
|
Neoplasms | 3 | 2023 | 22072 | 0.210 |
Why?
|
Hypertension | 2 | 2022 | 8594 | 0.210 |
Why?
|
MicroRNAs | 3 | 2023 | 3790 | 0.210 |
Why?
|
Quality of Life | 2 | 2022 | 13308 | 0.210 |
Why?
|
Thromboembolism | 3 | 2024 | 1017 | 0.210 |
Why?
|
Pravastatin | 2 | 2016 | 393 | 0.210 |
Why?
|
Angioplasty, Balloon | 3 | 2023 | 597 | 0.200 |
Why?
|
Ticlopidine | 5 | 2016 | 895 | 0.200 |
Why?
|
Heptanoic Acids | 2 | 2015 | 347 | 0.200 |
Why?
|
Europe | 3 | 2021 | 3441 | 0.200 |
Why?
|
Diabetic Nephropathies | 2 | 2019 | 988 | 0.190 |
Why?
|
Glomerular Filtration Rate | 3 | 2019 | 2180 | 0.190 |
Why?
|
Thromboplastin | 1 | 2023 | 286 | 0.190 |
Why?
|
Internationality | 3 | 2022 | 1004 | 0.190 |
Why?
|
Stroke Volume | 4 | 2023 | 5523 | 0.190 |
Why?
|
Aged, 80 and over | 13 | 2024 | 58995 | 0.180 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 71 | 0.180 |
Why?
|
Angioplasty | 1 | 2023 | 361 | 0.180 |
Why?
|
Glucagon-Like Peptides | 1 | 2022 | 159 | 0.180 |
Why?
|
Coronary Artery Bypass | 3 | 2016 | 2272 | 0.180 |
Why?
|
Aortic Aneurysm | 2 | 2016 | 648 | 0.180 |
Why?
|
Arteries | 2 | 2022 | 1126 | 0.170 |
Why?
|
Angiography | 2 | 2024 | 1605 | 0.170 |
Why?
|
Cohort Studies | 10 | 2022 | 41335 | 0.170 |
Why?
|
Symporters | 1 | 2022 | 361 | 0.160 |
Why?
|
Methylamines | 1 | 2020 | 138 | 0.160 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 31 | 0.160 |
Why?
|
Angina, Unstable | 3 | 2013 | 926 | 0.160 |
Why?
|
Appetite Regulation | 1 | 2019 | 84 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 792 | 0.160 |
Why?
|
Hospital Mortality | 3 | 2021 | 5425 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20509 | 0.150 |
Why?
|
Risk | 5 | 2019 | 9631 | 0.150 |
Why?
|
Mobility Limitation | 1 | 2022 | 402 | 0.150 |
Why?
|
Cardiovascular System | 2 | 2022 | 850 | 0.150 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8552 | 0.150 |
Why?
|
Polyethylene Glycols | 1 | 2023 | 1189 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 504 | 0.150 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2021 | 626 | 0.150 |
Why?
|
Exercise Therapy | 3 | 2022 | 919 | 0.150 |
Why?
|
Pyrroles | 2 | 2015 | 1137 | 0.140 |
Why?
|
Adamantane | 1 | 2018 | 169 | 0.140 |
Why?
|
Registries | 6 | 2024 | 8469 | 0.140 |
Why?
|
Myocardial Revascularization | 4 | 2021 | 841 | 0.140 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8056 | 0.140 |
Why?
|
Clinical Chemistry Tests | 2 | 2015 | 59 | 0.140 |
Why?
|
Doxorubicin | 1 | 2023 | 2209 | 0.140 |
Why?
|
Tissue Plasminogen Activator | 1 | 2022 | 1190 | 0.140 |
Why?
|
Peptide Fragments | 2 | 2023 | 5125 | 0.140 |
Why?
|
Placebos | 1 | 2021 | 1668 | 0.130 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 393 | 0.130 |
Why?
|
Dipeptides | 1 | 2018 | 409 | 0.130 |
Why?
|
Obesity | 4 | 2019 | 12922 | 0.130 |
Why?
|
Glycopeptides | 2 | 2014 | 220 | 0.130 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2009 | 638 | 0.130 |
Why?
|
Uracil | 1 | 2017 | 207 | 0.130 |
Why?
|
Blood Coagulation | 1 | 2021 | 1157 | 0.130 |
Why?
|
Aortitis | 1 | 2016 | 74 | 0.130 |
Why?
|
Adult | 20 | 2024 | 219994 | 0.130 |
Why?
|
Peripheral Vascular Diseases | 1 | 2018 | 515 | 0.130 |
Why?
|
Calibration | 1 | 2018 | 816 | 0.130 |
Why?
|
Platelet Activation | 2 | 2017 | 660 | 0.130 |
Why?
|
Lipoprotein(a) | 1 | 2020 | 499 | 0.120 |
Why?
|
Hemoglobins | 1 | 2021 | 1521 | 0.120 |
Why?
|
Thiazoles | 1 | 2022 | 1511 | 0.120 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2018 | 488 | 0.120 |
Why?
|
Anti-Obesity Agents | 1 | 2018 | 229 | 0.120 |
Why?
|
Research Personnel | 1 | 2020 | 582 | 0.120 |
Why?
|
Pericarditis | 1 | 2016 | 135 | 0.120 |
Why?
|
Benzaldehydes | 1 | 2014 | 59 | 0.120 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 992 | 0.120 |
Why?
|
Cyclopropanes | 1 | 2016 | 431 | 0.120 |
Why?
|
Venous Thrombosis | 2 | 2024 | 1299 | 0.120 |
Why?
|
Comorbidity | 3 | 2020 | 10551 | 0.120 |
Why?
|
Microcirculation | 1 | 2019 | 1278 | 0.120 |
Why?
|
Vascular Grafting | 1 | 2016 | 154 | 0.120 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15840 | 0.120 |
Why?
|
Kidney | 2 | 2020 | 7064 | 0.110 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2315 | 0.110 |
Why?
|
Biological Assay | 2 | 2015 | 630 | 0.110 |
Why?
|
Marketing | 1 | 2016 | 220 | 0.110 |
Why?
|
Warfarin | 1 | 2022 | 1518 | 0.110 |
Why?
|
Vascular Patency | 1 | 2016 | 901 | 0.110 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2023 | 1446 | 0.110 |
Why?
|
France | 3 | 2019 | 511 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1091 | 0.110 |
Why?
|
Immunotherapy | 2 | 2019 | 4642 | 0.110 |
Why?
|
Oximes | 1 | 2014 | 306 | 0.110 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 687 | 0.110 |
Why?
|
Ischemic Attack, Transient | 2 | 2015 | 901 | 0.110 |
Why?
|
Inflammation | 3 | 2023 | 10756 | 0.110 |
Why?
|
Weight Loss | 3 | 2019 | 2686 | 0.110 |
Why?
|
Diabetic Angiopathies | 1 | 2018 | 822 | 0.100 |
Why?
|
Simvastatin | 1 | 2015 | 352 | 0.100 |
Why?
|
Morbidity | 1 | 2018 | 1765 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2021 | 1380 | 0.100 |
Why?
|
Coronary Angiography | 1 | 2024 | 4563 | 0.100 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 796 | 0.100 |
Why?
|
Calgranulin A | 1 | 2012 | 80 | 0.100 |
Why?
|
Drug Approval | 2 | 2019 | 816 | 0.100 |
Why?
|
Calgranulin B | 1 | 2012 | 86 | 0.100 |
Why?
|
Retrospective Studies | 7 | 2024 | 80372 | 0.100 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 14660 | 0.100 |
Why?
|
Exercise Tolerance | 1 | 2017 | 830 | 0.100 |
Why?
|
Sleep Apnea Syndromes | 1 | 2020 | 974 | 0.100 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2013 | 296 | 0.100 |
Why?
|
Uncertainty | 1 | 2016 | 754 | 0.100 |
Why?
|
Osteoprotegerin | 1 | 2012 | 177 | 0.090 |
Why?
|
Pregnancy Proteins | 1 | 2012 | 222 | 0.090 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2065 | 0.090 |
Why?
|
Veterans | 2 | 2022 | 2642 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2018 | 888 | 0.090 |
Why?
|
Adiponectin | 1 | 2017 | 1115 | 0.090 |
Why?
|
Intestines | 1 | 2020 | 1907 | 0.090 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 15289 | 0.090 |
Why?
|
Heart Diseases | 2 | 2016 | 2809 | 0.090 |
Why?
|
Reoperation | 1 | 2021 | 4291 | 0.090 |
Why?
|
Overweight | 2 | 2018 | 2421 | 0.090 |
Why?
|
Down-Regulation | 1 | 2017 | 2913 | 0.090 |
Why?
|
Survival Analysis | 2 | 2014 | 10182 | 0.090 |
Why?
|
Guideline Adherence | 1 | 2020 | 2283 | 0.090 |
Why?
|
Heart | 1 | 2023 | 4393 | 0.090 |
Why?
|
Inpatients | 1 | 2021 | 2581 | 0.090 |
Why?
|
Subclavian Steal Syndrome | 1 | 2009 | 20 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20080 | 0.080 |
Why?
|
Infusions, Intravenous | 2 | 2024 | 2234 | 0.080 |
Why?
|
Blood Proteins | 1 | 2014 | 1173 | 0.080 |
Why?
|
Bacteria | 1 | 2020 | 2199 | 0.080 |
Why?
|
ROC Curve | 2 | 2014 | 3568 | 0.080 |
Why?
|
Troponin C | 1 | 2008 | 24 | 0.080 |
Why?
|
International Cooperation | 2 | 2013 | 1433 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2018 | 2001 | 0.080 |
Why?
|
Piperidines | 1 | 2017 | 1650 | 0.080 |
Why?
|
Age Factors | 3 | 2022 | 18416 | 0.080 |
Why?
|
Obesity, Abdominal | 1 | 2011 | 374 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3388 | 0.070 |
Why?
|
Femoral Artery | 2 | 2022 | 835 | 0.070 |
Why?
|
Protein Precursors | 2 | 2014 | 1134 | 0.070 |
Why?
|
Health Care Costs | 1 | 2021 | 3258 | 0.070 |
Why?
|
Natriuretic Peptides | 1 | 2008 | 156 | 0.070 |
Why?
|
Smoking | 2 | 2021 | 9073 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 1 | 2022 | 3218 | 0.070 |
Why?
|
Coronary Disease | 2 | 2018 | 5990 | 0.070 |
Why?
|
Young Adult | 5 | 2022 | 58741 | 0.070 |
Why?
|
Platelet Function Tests | 2 | 2018 | 303 | 0.070 |
Why?
|
Emergency Service, Hospital | 3 | 2017 | 7818 | 0.060 |
Why?
|
Neovascularization, Physiologic | 2 | 2023 | 1336 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11712 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8624 | 0.060 |
Why?
|
Kidney Neoplasms | 1 | 2022 | 4312 | 0.060 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1469 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3465 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3426 | 0.060 |
Why?
|
Sleep | 1 | 2020 | 4751 | 0.060 |
Why?
|
Gangrene | 1 | 2024 | 91 | 0.060 |
Why?
|
Internet | 1 | 2016 | 3078 | 0.060 |
Why?
|
C-Reactive Protein | 2 | 2016 | 3839 | 0.050 |
Why?
|
Mental Disorders | 1 | 2023 | 6796 | 0.050 |
Why?
|
Death | 2 | 2020 | 678 | 0.050 |
Why?
|
Bayes Theorem | 2 | 2023 | 2326 | 0.050 |
Why?
|
Inhibins | 1 | 2023 | 209 | 0.050 |
Why?
|
Child, Preschool | 2 | 2022 | 42063 | 0.050 |
Why?
|
Algorithms | 2 | 2020 | 13981 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9467 | 0.050 |
Why?
|
Adolescent | 4 | 2023 | 87810 | 0.050 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 2825 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5870 | 0.050 |
Why?
|
Therapeutics | 1 | 2022 | 114 | 0.050 |
Why?
|
Prevalence | 4 | 2019 | 15687 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12626 | 0.050 |
Why?
|
Absorbable Implants | 1 | 2023 | 345 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2012 | 1925 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2018 | 4775 | 0.050 |
Why?
|
Body Weight | 2 | 2023 | 4611 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2023 | 3539 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5643 | 0.040 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2022 | 503 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 2021 | 318 | 0.040 |
Why?
|
Necrosis | 1 | 2023 | 1612 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12159 | 0.040 |
Why?
|
Heart Ventricles | 1 | 2010 | 3811 | 0.040 |
Why?
|
Diuresis | 1 | 2018 | 107 | 0.040 |
Why?
|
Coronary Stenosis | 1 | 2024 | 820 | 0.040 |
Why?
|
Recovery of Function | 2 | 2019 | 2985 | 0.040 |
Why?
|
New Zealand | 1 | 2018 | 355 | 0.040 |
Why?
|
Patient Discharge | 1 | 2010 | 3476 | 0.040 |
Why?
|
Child | 2 | 2022 | 79806 | 0.040 |
Why?
|
Drug Labeling | 1 | 2019 | 251 | 0.040 |
Why?
|
Tissue Scaffolds | 1 | 2023 | 928 | 0.030 |
Why?
|
Pregnancy | 2 | 2024 | 29749 | 0.030 |
Why?
|
Sodium | 1 | 2022 | 1594 | 0.030 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2017 | 124 | 0.030 |
Why?
|
Republic of Korea | 1 | 2018 | 566 | 0.030 |
Why?
|
Body Mass Index | 3 | 2023 | 12914 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 629 | 0.030 |
Why?
|
England | 1 | 2017 | 526 | 0.030 |
Why?
|
Florida | 1 | 2017 | 430 | 0.030 |
Why?
|
Advisory Committees | 1 | 2020 | 788 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2020 | 699 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 1959 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2019 | 488 | 0.030 |
Why?
|
Sweden | 1 | 2018 | 1381 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 409 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 5508 | 0.030 |
Why?
|
Marfan Syndrome | 1 | 2016 | 236 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 584 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2023 | 3442 | 0.030 |
Why?
|
NF-kappa B | 1 | 2022 | 2488 | 0.030 |
Why?
|
Aorta | 1 | 2021 | 2039 | 0.030 |
Why?
|
Sex Factors | 2 | 2021 | 10547 | 0.030 |
Why?
|
Evidence-Based Medicine | 2 | 2017 | 3696 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 708 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2022 | 22053 | 0.030 |
Why?
|
Retinal Diseases | 1 | 2019 | 702 | 0.030 |
Why?
|
Sodium Channel Blockers | 1 | 2014 | 172 | 0.030 |
Why?
|
Cerebral Infarction | 1 | 2018 | 982 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 702 | 0.030 |
Why?
|
Atrial Natriuretic Factor | 1 | 2014 | 350 | 0.030 |
Why?
|
Insulin | 2 | 2018 | 6597 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 1259 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2392 | 0.030 |
Why?
|
Plaque, Atherosclerotic | 1 | 2024 | 1518 | 0.030 |
Why?
|
Limit of Detection | 1 | 2013 | 280 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 550 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1791 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1109 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2024 | 2125 | 0.020 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2018 | 1031 | 0.020 |
Why?
|
Animals | 5 | 2023 | 167963 | 0.020 |
Why?
|
Disease Progression | 2 | 2019 | 13502 | 0.020 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 1523 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2018 | 965 | 0.020 |
Why?
|
Mice | 3 | 2023 | 81208 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2017 | 1135 | 0.020 |
Why?
|
Hip Fractures | 1 | 2019 | 989 | 0.020 |
Why?
|
Long-Term Care | 1 | 2015 | 632 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4122 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2022 | 3484 | 0.020 |
Why?
|
Primary Prevention | 1 | 2018 | 1207 | 0.020 |
Why?
|
Vaccination | 1 | 2023 | 3361 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2017 | 1602 | 0.020 |
Why?
|
Norway | 1 | 2012 | 496 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2023 | 4166 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 3061 | 0.020 |
Why?
|
Health Promotion | 1 | 2022 | 2206 | 0.020 |
Why?
|
Retreatment | 1 | 2012 | 600 | 0.020 |
Why?
|
Metformin | 1 | 2018 | 912 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4351 | 0.020 |
Why?
|
Treatment Failure | 1 | 2016 | 2648 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 3804 | 0.020 |
Why?
|
Exercise Test | 1 | 2017 | 2128 | 0.020 |
Why?
|
Publishing | 1 | 2016 | 836 | 0.020 |
Why?
|
Creatine Kinase, MB Form | 1 | 2009 | 211 | 0.020 |
Why?
|
Curriculum | 1 | 2022 | 3718 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9287 | 0.020 |
Why?
|
Atherectomy | 1 | 2008 | 40 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3736 | 0.020 |
Why?
|
Creatinine | 1 | 2014 | 1903 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2017 | 2440 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13314 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14495 | 0.020 |
Why?
|
Waist Circumference | 1 | 2011 | 926 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1570 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 2041 | 0.020 |
Why?
|
Anthropometry | 1 | 2011 | 1348 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2543 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3534 | 0.020 |
Why?
|
Clinical Competence | 1 | 2022 | 4783 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1677 | 0.020 |
Why?
|
Aortic Valve | 1 | 2016 | 1996 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5325 | 0.020 |
Why?
|
Mortality | 1 | 2017 | 2916 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9716 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8525 | 0.010 |
Why?
|
Transcription Factors | 1 | 2022 | 12103 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 17790 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26181 | 0.010 |
Why?
|
Hemodynamics | 1 | 2011 | 4174 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25942 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8803 | 0.010 |
Why?
|
Signal Transduction | 1 | 2023 | 23376 | 0.010 |
Why?
|
Infant | 1 | 2022 | 36060 | 0.010 |
Why?
|
Preoperative Care | 1 | 2008 | 2256 | 0.010 |
Why?
|
Echocardiography | 1 | 2010 | 4981 | 0.010 |
Why?
|
Research Design | 1 | 2009 | 6180 | 0.010 |
Why?
|